Your browser is no longer supported. Please, upgrade your browser.
Zogenix, Inc.
Index- P/E- EPS (ttm)-4.30 Insider Own0.30% Shs Outstand55.75M Perf Week5.08%
Market Cap1.01B Forward P/E- EPS next Y-1.83 Insider Trans14.12% Shs Float55.57M Perf Month-2.10%
Income-239.20M PEG- EPS next Q-0.93 Inst Own- Short Float15.99% Perf Quarter-11.13%
Sales26.10M P/S38.67 EPS this Y60.00% Inst Trans3.59% Short Ratio13.10 Perf Half Y-13.13%
Book/sh5.76 P/B3.16 EPS next Y47.00% ROA-38.60% Target Price- Perf Year-36.70%
Cash/sh7.85 P/C2.32 EPS next 5Y8.80% ROE-63.00% 52W Range16.73 - 32.42 Perf YTD-8.95%
Dividend- P/FCF- EPS past 5Y-14.90% ROI-44.40% 52W High-43.86% Beta1.41
Dividend %- Quick Ratio7.70 Sales past 5Y-12.90% Gross Margin95.30% 52W Low8.79% ATR0.67
Employees218 Current Ratio7.80 Sales Q/Q336.20% Oper. Margin- RSI (14)53.15 Volatility3.49% 3.44%
OptionableYes Debt/Eq0.47 EPS Q/Q-86.40% Profit Margin- Rel Volume0.91 Prev Close17.92
ShortableYes LT Debt/Eq0.47 EarningsMay 06 AMC Payout- Avg Volume678.25K Price18.20
Recom1.70 SMA201.79% SMA50-1.95% SMA200-10.12% Volume616,689 Change1.56%
Aug-25-20Initiated Raymond James Mkt Perform
Mar-06-20Initiated Citigroup Neutral $27
Feb-07-20Reiterated Needham Buy $58 → $54
Feb-07-20Downgrade Ladenburg Thalmann Buy → Neutral $35
Oct-21-19Initiated Needham Buy $58
Jun-27-19Upgrade Guggenheim Neutral → Buy $40 → $64
Apr-09-19Downgrade Guggenheim Buy → Neutral
Nov-05-18Initiated Piper Jaffray Overweight
Sep-14-18Initiated BofA/Merrill Buy $63
Sep-12-18Initiated Northland Capital Outperform $70
Sep-07-18Initiated B. Riley FBR Buy $116
Aug-23-18Initiated Ladenburg Thalmann Buy $71
Aug-15-18Resumed Stifel Buy $65 → $69
Jul-13-18Reiterated Stifel Buy $55 → $65
Nov-27-17Initiated JMP Securities Mkt Outperform
Oct-03-17Reiterated Mizuho Buy $28 → $51
Sep-29-17Upgrade William Blair Mkt Perform → Outperform
Oct-04-16Resumed Leerink Partners Outperform $17
Aug-11-15Reiterated Oppenheimer Outperform $20 → $23
Jul-15-15Reiterated Brean Capital Buy $20 → $28
May-25-21 08:46AM  
May-11-21 04:01PM  
May-06-21 06:45PM  
Apr-29-21 05:04PM  
Apr-27-21 08:00AM  
Apr-22-21 10:51AM  
Apr-16-21 08:00AM  
Apr-14-21 11:56AM  
Apr-08-21 10:47AM  
Mar-25-21 08:00AM  
Mar-08-21 11:15AM  
Mar-02-21 08:00AM  
Feb-25-21 04:01PM  
Feb-18-21 08:00AM  
Feb-16-21 01:27PM  
Feb-11-21 08:00AM  
Feb-03-21 04:25PM  
Feb-02-21 08:52AM  
Feb-01-21 10:05PM  
Jan-11-21 08:00AM  
Dec-22-20 05:12PM  
Dec-21-20 08:00AM  
Dec-17-20 04:39AM  
Dec-03-20 05:42PM  
Dec-01-20 08:00AM  
Nov-11-20 09:27AM  
Nov-09-20 10:30PM  
Nov-06-20 08:42AM  
Nov-03-20 03:27PM  
Nov-02-20 12:31PM  
Oct-29-20 08:00AM  
Oct-28-20 03:13PM  
Oct-26-20 08:00AM  
Oct-16-20 08:00AM  
Oct-15-20 04:16PM  
Oct-05-20 04:03PM  
Oct-02-20 08:00AM  
Sep-23-20 11:00PM  
Sep-22-20 04:14PM  
Sep-21-20 08:04PM  
Sep-11-20 11:32AM  
Sep-10-20 08:24AM  
Sep-09-20 12:33PM  
Aug-18-20 04:56PM  
Aug-05-20 10:15PM  
Jul-29-20 08:00AM  
Jul-28-20 12:33PM  
Jul-13-20 05:03PM  
Jul-05-20 03:45PM  
Jul-02-20 08:53AM  
Jul-01-20 09:43AM  
Jun-29-20 06:53PM  
Jun-26-20 10:48AM  
Jun-25-20 11:05PM  
Jun-21-20 02:53PM  
Jun-19-20 10:09PM  
Jun-12-20 08:00AM  
Jun-10-20 06:19AM  
Jun-03-20 03:10AM  
May-28-20 11:24AM  
May-27-20 09:37PM  
May-15-20 08:00AM  
May-06-20 06:00PM  
May-05-20 07:05PM  
May-04-20 08:55AM  
Apr-28-20 12:56PM  
Apr-20-20 08:00AM  
Apr-16-20 09:46AM  
Apr-15-20 08:00AM  
Apr-07-20 02:16PM  
Mar-29-20 12:31PM  
Mar-24-20 07:52AM  
Mar-21-20 09:08AM  
Mar-06-20 04:05PM  
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANNENBAUM RENEE PDirectorJun 01Buy17.055,00085,24737,872Jun 03 07:20 PM
Waynick Denelle JDirectorJun 01Buy17.075849,969584Jun 03 07:20 PM
GARNER CAM LDirectorMay 10Buy19.0315,000285,49631,000May 12 08:00 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 15Option Exercise0.005,218022,258Mar 17 04:04 PM
FARR STEPHEN JPresident and CEOMar 15Option Exercise0.0016,875093,212Mar 17 04:03 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Mar 15Option Exercise0.005,21807,585Mar 17 04:03 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMar 15Option Exercise0.004,531013,484Mar 17 04:02 PM
Farfel Gail MEVP/Chief Development OfficerMar 15Option Exercise0.005,156015,318Mar 17 04:02 PM
GARNER CAM LDirectorNov 19Buy20.138,000161,04216,000Nov 20 05:15 PM
TANNENBAUM RENEE PDirectorNov 17Sale20.7415,000311,06632,872Nov 18 05:05 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERJul 02Option Exercise0.003,750010,232Jul 06 04:37 PM
Galer Bradley S.EVP/Chief Medical OfficerJun 25Option Exercise0.0010,000020,015Jun 29 09:53 PM
Farfel Gail MEVP/Chief Development OfficerJun 25Option Exercise0.008,750014,223Jun 29 09:54 PM